QTTB: q32bio.com Company Value to Net Income
Q32 Bio Inc. (QTTB) focuses on clinical trials, expanding its scientific potential through alliances with pharma behemoths without pursuing mergers. The company's revenues will be based on bringing immune response correction agents for severe inflammation to market. This chart reflects a current market valuation of 8.40. Additionally, the business is studying the complement system to create therapies for treating kidney pathologies.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_QTTB_-_Q32-Bio-Inc._-_PE-Multiple "QTTB: Q32 Bio Corp Business Payback Period 03/27/2024 - 11/12/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Q32 Bio Inc (QTTB)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
QTTB - Net Income|Expected Profit Q32 Bio Inc.|QTTB - Price to Earnings Ratio|Future Price to Earnings Multiple Q32 Bio Corp|QTTB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Q32 Bio Inc.|QTTB - Operating profit EBITDA|Net earnings per share for the last four quarters Q32 Bio|QTTB - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months q32bio.com|QTTB - Net earnings per share growth this year|Expected earnings per share trend next year Q32 Bio Inc.
Comprehensive company analysis:q32bio.com QTTB
When screening for issuer reliability, an investor utilizes the company's P/E ratio, calculated as the ratio of market capitalization to net income, to measure the cost of one dollar of earnings. The current value of 8.40 reflects market expectations for the fusion protein development of Q32 Bio Inc. (QTTB), where the company's P/E trend links the value of innovative immunotherapy to the business's actual ability to generate profit.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Market Cap to Net Income Ratio Tourmaline (TRML)|PGEN (Precigen, Inc.) - Price to Earnings Ratio|PHAR (pharming.com) - Price to Earnings Ratio|Price to Earnings Ratio NKTR|UPB: Company Value to Net Income|P/E Multiple ZBIO|Price to Earnings Ratio IMNM (Immunome Bio)|P/E Multiple GOSS (Gossamer Bio, Inc.)|Business Payback Period kalvista.com (KALV)|SEPN - Price to Earnings Ratio|Market Cap to Earnings Pieris Pharma|SVRA (Savara Corp) - Price to Earnings Ratio|Rigel Corp - Company Value to Net Income|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT Therapeutics Inc. - Price to Earnings Multiple|P/E Multiple JBIO (Aerovate Therapeutics)|ACRS - Price to Earnings Ratio|KYTX: Price to Earnings Ratio|Business Payback Period tizianalifesciences.com TLSA|Cabaletta Bio (CABA) - Price to Earnings Ratio|Market Cap to Net Income Ratio Ventyx Biosciences Inc. VTYX|Price to Earnings Ratio THTX|AVTX (Avalo Therapeutics Inc) - Market Price to Net Income Ratio|Price to Earnings Ratio ELDN (Eledon Pharmaceuticals)|Market Price to Net Income Ratio AGEN|P/E Multiple CLYM (Climb Bio)|Zura Bio Ltd - Price to Earnings Ratio|ATYR - Price to Earnings Ratio|Market Cap to Net Income ADAG|IMA: P/E Multiple|Shattuck Labs - Company Value to Net Income|EQ (Equillium Inc) - P/E Multiple|P/E Multiple Connect Pharma|Price to Earnings Ratio Immunic, Inc. (IMUX)|ATRA (atarabio.com) - Company Value to Net Income|Price to Earnings Ratio InflaRx IFRX|XFOR - Price to Earnings Ratio|Adicet - P/E Multiple|CELU - P/E Multiple|INMB (INmune Bio Corp) - Price to Earnings Ratio|Barinthus Biotherapeutics Corp - Company Value to Net Income|KZR (Kezar Life Sciences) - P/E Multiple|sabbiotherapeutics.com (SABS) - Business Payback Period|Price to Earnings Ratio Akari Therapeutics Plc (AKTX)|Price to Earnings Ratio enlivex.com ENLV|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA - Price to Earnings Ratio|IBIO: Price to Earnings Ratio|CARM - P/E Multiple|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Multiple BOLT|HCWB (HCW Biologics, Inc.) - P/E Multiple|Market Cap to Earnings Aptevo APVO|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|aditxt.com (ADTX) - Market Cap to Net Income Ratio|GRI Bio - Price to Earnings Ratio|XORTX Therapeutics Inc - Price to Earnings Ratio|HIND: Price to Earnings Ratio|Company Value to Net Income REVB (Revelation Biosciences Corp)|INDP: P/E Multiple|SCNI (scinai.com) - Price to Earnings Ratio|CALI (CalciMedica Inc) - P/E Multiple|Affimed Therapeutics (AFMD) - Business Payback Period|Price to Earnings Ratio Allakos Inc. (ALLK)|HOOK - Market Cap to Earnings|IGM Biosciences - Price to Earnings Ratio|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|Business Payback Period TC BioPharm (Holdings) Plc TCBP|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
